Investigating the association between neoplasms and MOG antibody-associated disease

The association of myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD) and tumors has seldom been reported. We aim to investigate the occurrence of tumors in a cohort of patients with MOGAD and to describe their clinical features, in addition to previously reported cases. W...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Frontiers in neurology Ročník 14; s. 1193211
Hlavní autoři:	Trentinaglia, Milena, Dinoto, Alessandro, Carta, Sara, Chiodega, Vanessa, Ferrari, Sergio, Andreone, Vincenzo, Maniscalco, Giorgia Teresa, Mariotto, Sara
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 09.06.2023
Témata:	cancer immune checkpoint inhibitors myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) Neurology paraneoplastic neurological syndrome tumor paraneoplastic neurological syndrome cancer immune checkpoint inhibitors myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) tumor
ISSN:	1664-2295, 1664-2295
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The association of myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD) and tumors has seldom been reported. We aim to investigate the occurrence of tumors in a cohort of patients with MOGAD and to describe their clinical features, in addition to previously reported cases. We retrospectively identified patients with MOGAD (i.e., compatible clinical phenotype and positive MOG antibodies analysed with a live cell-based assay) from 1/1/2015 to 1/1/2023 who had a neoplasm diagnosed within 2 years from MOGAD onset. Furthermore, we performed systematic review of literature to identify previously reported cases. Clinical, paraclinical and oncological findings were collected and reported as median (range) or number (percentage). Two of 150 MOGAD patients (1%) had a concomitant neoplasm in our cohort. Fifteen additional cases were retrieved from literature. Median age was 39 (16-73) years-old, 12 patients were female. ADEM ( = 4;23.5%), encephalomyelitis ( = 3;17.6%), and monolateral optic neuritis ( = 2;11.8%) were the most frequent phenotypes. Median number of treatments was 1 (range 1-4), improvement was reported in 14/17 cases (82.4%). Oncological accompaniments were teratoma ( = 4), CNS ( = 3), melanoma ( = 2), lung ( = 2), hematological ( = 2), ovary ( = 1), breast ( = 1), gastrointestinal ( = 1), and thymic ( = 1) neoplasms. Median time from tumor diagnosis to MOGAD onset was 0 (range - 60 to 20) months. MOG expression in neoplastic tissue was reported in 2/4 patients. Median PNS-CARE score was 3 (range 0-7): 11 patients were classified as "non-PNS," 5 as "possible PNS," and 1 as "probable PNS." Our study confirms that MOG is a low-risk antibody for paraneoplastic neurological syndromes and that the clinical presentation and oncological accompaniments are extremely variable. Most of these patients were classified as non-PNS, whereas only a minority was diagnosed with possible/probable PNS, frequently in association with ovarian teratoma. These findings support the notion that MOGAD is not a paraneoplastic disease.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors share senior authorship Reviewed by: Masako Kinoshita, National Hospital Organization Utano National Hospital, Japan; Sergio Muñiz-Castrillo, Stanford Center for Sleep Sciences and Medicine, United States These authors have contributed equally to this work Edited by: Sasitorn Siritho, Bumrungrad International Hospital, Thailand
ISSN:	1664-2295 1664-2295
DOI:	10.3389/fneur.2023.1193211